Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 10/20 | 1.00 |
| ▸ | DRD2 | P14416 | 6/20 | 1.00 |
| ▸ | DRD4 | P21917 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD5 | P21918 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxanthrine SCHEMBL13963768 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD4ADRA2AADRA2B | |
| Doxanthrine SCHEMBL7943399 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD4ADRA2AADRA2B | |
| Doxanthrine SCHEMBL13963759 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD4ADRA2AADRA2B | |
| Doxanthrine SCHEMBL13974053 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD4ADRA2AADRA2B | |
| Doxanthrine SCHEMBL4507980 | 0.99 | DRD1 (0.97) | DRD1DRD2DRD4ADRA2AADRA2B | |
| Doxanthrine SCHEMBL3879181 | 0.99 | DRD1 (0.97) | DRD1DRD2DRD4ADRA2AADRA2B | |
| Doxanthrine SCHEMBL3882738 | 0.99 | DRD1 (0.97) | DRD1DRD2DRD4ADRA2AADRA2B | |
| SCHEMBL13963755 | 0.83 | DRD1 (0.71) | DRD1DRD2DRD4ADRA2AADRA2B | |
| SCHEMBL13974052 | 0.83 | DRD1 (0.71) | DRD1DRD2DRD4ADRA2AADRA2B | |
| SCHEMBL3952852 | 0.83 | DRD1 (0.71) | DRD1DRD2DRD4ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| EP-4378532-B1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-12 | — | — | EP | claimed |
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | claimed |
| EP-4618976-A1 | COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL CONDITIONS | Dri Biosciences Corporation (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-06-05 | — | — | US | claimed |
| CN-112770734-B | Inhibition method | 堪培拉大学 | 2024-08-20 | — | — | CN | claimed |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-08-01 | — | — | US | claimed |
| EP-4378532-A2 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2024-06-05 | — | — | EP | claimed |
| WO-2024107961-A1 | COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL CONDITIONS | DRI BIOSCIENCES CORPORATION (US) | 2024-05-23 | — | — | WO | claimed |
| EP-4335504-A2 | TREATMENT OF MOVEMENT DISORDERS | Contera Pharma ApS (DK) | 2024-03-13 | — | — | EP | claimed |
| US-11890266-B2 | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier | UNIVERSITY OF CANBERRA (AU) | 2024-02-06 | — | — | US | claimed |
| EP-3897641-B1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA AS (DK) | 2023-11-15 | — | — | EP | claimed |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-11-02 | — | — | US | claimed |
| US-11666547-B2 | Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1) | NORTHWESTERN UNIVERSITY (US) | 2023-06-06 | — | — | US | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| US-20220370471-A1 | COMPOSITION AND METHOD FOR TREATMENT OF HIPPOCAMPAL SYNAPSE DYSFUNCTION AND COGNITIVE DEFICITS IN ALZHEIMER'S DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-11-24 | — | — | US | claimed |
| EP-4003348-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2022-06-01 | — | — | EP | claimed |
| US-20220062279-A1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA A/S (DK) | 2022-03-03 | — | — | US | claimed |
| US-20220047529-A1 | METHODS OF INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2022-02-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD1 4883/4885DRD2 4882/4885DRD4 4877/4885 |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD1 4882/4885DRD2 4879/4885DRD4 4861/4885 |
| US-11666547-B2 | Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1) | SLC6A1, SLC6A3, SLC6A13 | DRD1 11/4885DRD2 18/4885DRD4 44/4885 |
| US-20220047529-A1 | METHODS OF INHIBITION | SLC6A3, DBH, SNCA | DRD1 4/4885DRD2 5/4885DRD4 8/4885 |
| US-11890266-B2 | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier | TTPA, TST, TXN2 | DRD1 1876/4885DRD2 2171/4885DRD4 2073/4885 |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD1 4882/4885DRD2 4879/4885DRD4 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.